Johnson & Johnson (JNJ) reported encouraging first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to enhance the immune system's ability to target advanced prostate cancer.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.